PATENT

Serial No. 10/524,316 Docket No.: 2839/46401

## Listing of Claims:

- 1. (Cancelled)
- 2. (Previously Presented) The method of claim 11 wherein the newborn subject is a mammal in the first four weeks after birth.
- 3. (Cancelled)
- 4. (Cancelled)
- (Previously Presented) The method of claim 11 wherein the xenon is administered in combination with a sedative, an anaesthetic agent or a further analgesic agent.
- 6. (Previously Presented) The method of claim 11 wherein the medicament is in gaseous form.
- 7. (Cancelled)
- 8. (Previously Presented) The method of claim 11 wherein the medicament is in liquid form.
- 9. (Cancelled)
- 10. (Cancelled)
- 11. (Currently Amended) A method of providing analgesia in a <u>human</u> newborn subject, the method comprising administering <u>a therapeutically effective amount of an analgesic</u> to a <u>human</u> newborn subject <u>experiencing pain or stress sufficient to necessitate administration of the analgesic, wherein the analgesic is xenon\_in need of analgesia a therapeutically effective amount of xenon.</u>

PATENT

Serial No. 10/524,316

Docket No.: 2839/46401

12. (Currently Amended) A method of providing analgesia in a <u>human</u> fetal subject, the method comprising administering <u>a therapeutically effective amount of an analgesic</u> to <u>a</u> the mother of <u>a</u> the <u>human</u> fetal subject, the fetal subject <u>experiencing pain or stress sufficient to necessitate administration of the analgesic</u>, wherein the <u>analgesic</u> is <u>xenon</u> in need of analgesia, a therapeutically effective amount of xenon the fetal subject.

- 13. (Previously Presented) A method accordingly to claim 11 wherein the xenon is administered in combination with a pharmaceutically acceptable carrier, diluent or excipient.
- 14. (Previously Presented) A method according to claim 11 wherein the xenon is administered in the form of a 20 to 70% v/v xenon/air mixture.
- 15. (Previously Presented) A method according to claim 11 wherein the xenon is administered in the form of a lipid emulsion.
- 16. (Previously Presented) A method according to claim 11 wherein the xenon is administered intraveneously, neuraxially or transdermally.
- 17. (Previously Presented) A method accordingly to claim 12 wherein the xenon is administered in combination with a pharmaceutically acceptable carrier, diluent or excipient.
- 18. (Previously Presented) A method according to claim 12 wherein the xenon is administered in the form of a 20 to 70% v/v xenon/air mixture.
- 19. (Previously Presented) A method according to claim 12 wherein the xenon is administered in the form of a lipid emulsion.
- (Previously Presented) A method according to claim 12 wherein the xenon is administered intraveneously, neuraxially or transdermally.

PATENT

Serial No. 10/524,316

Docket No.: 2839/46401

21. (Previously Presented) The method according to claim 12, wherein the xenon is administered to the mother prior to labor.

- 22. (Previously Presented) The method according to claim 12, wherein the xenon is administered to the mother during labor.
- 23. (Previously Presented) The method of claim 5, wherein the further analysesic agent is an alpha-2-adrenergic agonist, an opiate, or a non-steroidal anti-inflammatory drug.
- 24. (Previously Presented) The method of claim 5, wherein the sedative or anaesthetic agent promotes GABAergic activity.